Search clinical trials for: Vedolizumab Placebo

Total 53676 results

Takeda

Completed

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

Crohn's Disease

United States, Italy, Poland, France, Belgium, Canada, Hungary, Czechia
University of Thessaly

Recruiting

Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiation (IMPOSE)

Severe Asthma

Greece
St. Paul's Sinus Centre

Not yet recruiting

th2 Modulation CRSwNP

Chronic Rhinosinusitis With Nasal Polyps

Canada
Policlinico Universitario, Catania

Recruiting

Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis

Bronchiectasis | Bronchial Asthma

Italy
GlaxoSmithKline

Recruiting

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) (SPHERE)

Hypereosinophilic Syndrome

United States, Argentina, Spain, Turkey, Israel, Brazil, Mexico, United Kingdom
Galderma R&D

Completed

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

Atopic Dermatitis

United States
Galderma R&D

Completed

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

Hypereosinophilic Syndrome | Hypereosinophilia

United States, Belgium, Canada, Germany, Italy, France, Switzerland, Australia
GlaxoSmithKline

Completed

Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children

Asthma

Japan, United States, United Kingdom, Poland
GlaxoSmithKline

Completed

Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

Oesophagitis, Eosinophilic

United States, Canada, United Kingdom, Australia
GlaxoSmithKline

Terminated

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Hypereosinophilic Syndrome

United States, Belgium, Canada, Germany, Italy, France, Australia
University Hospital Schleswig-Holstein
GlaxoSmithKline

Completed

Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome (MEPOCHUSS)

Churg Strauss Syndrome

Germany
Alimentiv Inc.
Takeda

Not yet recruiting

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease (VECTORS)

Crohn Disease | Moderately to Severely Active Crohn's Disease | Disease Crohn
Pontifícia Universidade Católica do Paraná
Takeda

Unknown

Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy

Crohn Disease
Takeda

Completed

A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

Crohn Disease | Colitis, Ulcerative

China
Takeda

Completed

Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

Allogeneic Hematopoietic Stem Cell Transplantation

United States
Takeda

Completed

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Colitis, Ulcerative

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Allogeneic Hematopoietic Stem Cell Transplantation

United States, Belgium, Sweden, France, Norway
Bio-Thera Solutions

Completed

Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

Severe Asthma

China
GlaxoSmithKline

Not yet recruiting

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study (REIMAGINE)

Asthma
University of Crete

Recruiting

Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).

Severe Eosinophilic Asthma w/wo CRSwNP

Greece
Temple University
GlaxoSmithKline

Not yet recruiting

Immunological Basis for Mepolizumab Activity in COPD

COPD
Hospital Clinico Universitario de Santiago
GlaxoSmithKline

Recruiting

Effect of Mepolizumab on Severe Eosinophilic Asthma (EMESEA)

Asthma | Eosinophilic Asthma

Spain
Instituto de Investigación Marqués de Valdecilla

Not yet recruiting

Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. (MELYSA)

Rhinosinusitis Chronic | Polyp, Nasal

Spain
Galderma R&D

Recruiting

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Denmark, Hungary, Poland, Spain
Galderma R&D

Active, not recruiting

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Prurigo Nodularis

United States, Belgium, Canada, France, Korea, Republic of, Netherlands, Poland, Spain, Switzerland, Austria, Denmark, Germany, Hungary, Italy, Sweden, United Kingdom
Galderma R&D

Active, not recruiting

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom
Yonsei University

Not yet recruiting

Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease (VEDOKO-IIT)

Crohn's Disease and Ulcerative Colitis

Korea, Republic of
Takeda

Recruiting

A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis

Japan
University of Pennsylvania
Takeda; Corporal Michael J. Crescenz VA Medical Center

Withdrawn

An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis

Ulcerative Colitis

United States
Parc de Salut Mar

Completed

Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.

Inflammatory Bowel Disease

Spain
Rennes University Hospital

Recruiting

EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis (EFFICACI)

Ulcerative Colitis

France
University of Miami
Takeda

Completed

Synergistic Effect of Vedolizumab and Pentoxifylline

Crohn Disease

United States
Food and Drug Administration (FDA)
Spaulding Clinical Research LLC

Completed

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

Healthy Subjects | Pharmacokinetics | Pharmacodynamics

United States
Takeda

Terminated

Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

Crohn Disease | Colitis, Ulcerative

Korea, Republic of, Italy, India, Malaysia, Hungary, Serbia, Latvia, Australia, Estonia, Poland, South Africa, Czechia, Turkey, Bulgaria, New Zealand, Romania, Russian Federation, Ukraine
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Israel, United States, Hungary, Belgium, France, Poland, Ukraine, United Kingdom
Hospices Civils de Lyon
GlaxoSmithKline

Recruiting

Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices (SECURE)

Asthma

France
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

Crohn Disease

China
University Hospital Schleswig-Holstein

Completed

Clinical and Molecular Phenotyping in IBD (Phen_IBD)

IBD

Germany
Brigham and Women's Hospital
GlaxoSmithKline

Completed

Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome (MATOCSS)

Churg Strauss Syndrome

United States
University of Wisconsin, Madison

Completed

Eosinophilic Airway Inflammation and Mepolizumab

Asthma

United States
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Recruiting

A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD (SUMMER)

COPD

United Kingdom
Medical Centre Leeuwarden
GlaxoSmithKline

Completed

Use of Nucala in Severe Asthma (UNISA)

Asthma Severe Persistent Uncontrolled

Netherlands
Galderma R&D

Withdrawn

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

Moderate-to-severe Atopic Dermatitis
Eli Lilly and Company

Withdrawn

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)

Ulcerative Colitis
Takeda
The Organization of Teratology Information Specialists

Completed

OTIS Vedolizumab Pregnancy Exposure Registry

Crohn's Disease | Colitis, Ulcerative

United States
Alimentiv Inc.
Takeda Development Center Americas, Inc.

Recruiting

Determination of the Optimal Treatment Target in Ulcerative Colitis (VERDICT)

Colitis, Ulcerative

Canada, United Kingdom, Poland, Italy, United States, Belgium, France, Netherlands, Belarus, Ukraine
Takeda

Completed

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis (EARNEST)

Pouchitis

United States, Spain, United Kingdom, Canada, Germany, Netherlands, Italy, Belgium, France
GlaxoSmithKline

Completed

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

Asthma

United States, Argentina, Australia, Canada, France, Germany, Japan, Netherlands, Poland, Russian Federation, Spain, Ukraine, Belgium, Chile, Korea, Republic of, United Kingdom, Czechia, Mexico, Italy
Asan Medical Center

Recruiting

Prediction Model for Response to Biologics and Small Molecular Agent for UC

Ulcerative Colitis

Korea, Republic of

Search clinical trials for: Vedolizumab Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations